Summary
The effect and potential molecular mechanisms of berberine on gluconeogenesis in skeletal muscles and adipose tissues were investigated. After adaptive feeding for one week, 8 rats were randomly selected as the normal group and fed on a standard diet. The remaining 32 rats were fed on a high-fat diet and given an intravenous injection of streptozotocin (STZ) for 2 weeks to induce the diabetic models. The diabetic rat models were confirmed by oral glucose tolerance test (OGTT) and randomly divided into 4 groups (n=8 each), which were all fed on a high-fat diet. Berberine (3 g/kg per day) or metformin (183 mg/kg per day) was intragastrically administered to the diabetic rats for 12 weeks, serving as berberine group and metformin group respectively. 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside [AICAR, an agonist of AMP-activated protein kinase (AMPK), 0.5 mg/kg per day] was subcutaneously injected to the diabetic rats for 12 weeks, serving as AICAR group. The remaining 8 diabetic rats served as the model group, which was given a 0.5% carboxyl methylcellulose solution by oral gavage. Fasting serum insulin (FINS), OGTT as well as lipid parameters were tested by commercial kit. The protein levels of liver kinase B1 (LKB1), AMPK, phosphorylated AMP-activated protein kinase (p-AMPK), transducer of regulated CREB activity 2 (TORC2), phosphorylated transducer of regulated CREB activity 2 (p-TORC2), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in skeletal muscles and adipose tissues were examined by Western blotting. The results showed that berberine significantly decreased the body weight, plasma glucose, insulin levels, and homeostatic model assessment for insulin resistance (HOMA-IR) of diabetic rats compared with those in the model group. Meanwhile, the serum total triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels were markedly decreased and high-density lipoprotein cholesterol (HDL-C) level was significantly increased after the treatment with berberine. In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues. Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group. It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rowley WR, Bezold C, Arikan Y, et al. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag, 2017, 20(1):6–12
Hu F. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care, 2011, 34(6):1249–1257
Gastaldelli A. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract, 2011, 93:S60–S65
Liu XT, Li YQ, Li LL, et al. Prevalence, awareness, treatment, control of type 2 diabetes mellitus and risk factors in Chinese rural population: the RuralDiab study. Sci Rep, 2016, 6:31426
Tan MH, Alquraini H, Mizokami-Stout K, et al. Metformin: From Research to Clinical Practice. Endocrinol Metab Clin North Am, 2016, 45(4):819–843
Rios JL, Francini F, Schinella GR. Natural Products for the Treatment of Type 2 Diabetes Mellitus. Planta Med, 2015, 81(12–13):975–994
Sun Y, Xiong YY, Wu HZ, et al. Active Ingredients and Mechanism of Action of Rhizoma Coptidis against Type 2 Diabetes Based on Network-Pharmacology and Bioinformatics. Curr Med Sci, 2020, 40(2):257–264
Wang H, Zhu C, Ying Y, et al. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget, 2018, 9(11):10 135–10 146
Yan M, Qi H, Xia T, et al. Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKa. Metabolism, 2018, 91:18–29
Shen N, Huan Y, Shen ZF. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol, 2012,694(1–3): 120–126
Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009,296: E812–E819
Jiang SJ, Dong H, Li JB, et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol, 2015, 21(25):7777–7785
Chen G, Lu FE, Jin D, et al. Effect of Huanglian Jiedu decoction on glucose transporter 4 expression in adipose and skeletal muscle tissues of insulin resistant rats. Chin J Integr Med, 2007, 13(1):41–45
Defronzo RA, Jacot E, Jequier E, et al. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes, 1981, 30(12):1000–1007
Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol, 1999, 277:E1–E10
Miyaki A, Choi Y, Maeda S. Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice. Am J Med Sci, 2014, 347(3):228–233
Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab, 2005, 19(4):649–663
Zhang CY, Baffy G, Perret P, et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell, 2001, 105(6):745–755
Miller R A, Chu Q, Le Lay J, et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest, 2011, 121(6):2518–2528
Petersen MC, Vatner DF, Shulman GL. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol, 2017, 13(10):572–587
Coughlan KA, Valentine RJ, Ruderman NB, et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes, 2014,7:241–253
Wang Y, Vera L, Fischer WH, et al. The CREB coactivator CRTC2 links hepatic ER stress and fasting gluconeogenesis. Nature, 2009, 460(7254):534–537
Dentin R, Liu Y, Koo SH, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature, 2007, 449(7160):366–369
Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med, 2012,591654
Xia X, Yan JH, Shen YF, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6:e16556
Han X, Tao YL, Deng YP, et al. Metformin ameliorates insulitis in STZ-induced diabetic mice. PeerJ, 2017,5: e3155
Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005,310(5754):1642–1646
Rourke JL, Hu Q, Screaton RA. AMPK and Friends: Central Regulators of β Cell Biology. Trends Endocrinol Metab, 2018, 29(2):111–122
Zhang YP, Deng YJ, Tang KR, et al. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Curr Med Sci, 2019, 39(1):37–43
Canettieri G, Koo S H, Berdeaux R, et al. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab, 2005,2(5): 331–338
Kumar A, Harris TE, Keller SR, et al. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol, 2008,28(1):61–70
Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 2005, 437(7062):1109–1111
Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium- and cAMPsensitive coincidence detector. Cell, 2004,119(1): 61–74
Zhang WY, Zhang XL, Wang H, et al. AMP-activated protein kinase alpha1 protects against diet-induced insulin resistance and obesity. Diabetes, 2012,61,3114–3125
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Additional information
This project was supported by the National Natural Science Foundation of China (No. 81673757 and No. 81603652).
Rights and permissions
About this article
Cite this article
Xu, Xh., Hu, Q., Zhou, Ls. et al. Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway. CURR MED SCI 40, 530–538 (2020). https://doi.org/10.1007/s11596-020-2210-4
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-020-2210-4